-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Trastuzumab is the only targeted drug approved for the treatment of human epidermal growth factor receptor 2 positive (HER2+) metastatic gastric cancer (mGC).
Stomach cancer
The study conducted a prospective multicenter study to determine the resistance mechanism of mGC patients to HER2 targeted therapy.
Figure 1 Screenshot of the paper publication page
Figure 1 Screenshot of the paper publication page
It is estimated that gastric cancer is the fifth most common malignant tumor in the world, with more than 1 million new cases every year and a high mortality rate.
The study recruited patients receiving mGC treatment to 35 German research centers with a follow-up period of up to 48 months.
Figure 2 Technical route
Figure 2 Technical routeThe HER2 status was assessed intensively by immunohistochemistry and chromogenic in situ hybridization, and the expression of HER2 gene was detected by quantitative PCR.
immunity
The study did not establish a detailed statistical analysis plan, but made a rough estimate of the expected number of cases observed.
In the management of patients receiving trastuzumab combined with chemotherapy, patients with HER2 + mGC (HER2+/HER2 +, n=60) confirmed by the center had significantly longer OS than HER2-/HER2+ receiving trastuzumab combined with chemotherapy Patients tested (n = 65).
Figure 3 Center HER2 test results
Figure 3 Center HER2 test resultsThe study found that significant differences in HER2 evaluation of mGC were found in tumor specimens with moderate HER2 expression.
The degree of HER2 positivity and the heterogeneity of HER2 expression should be resistance factors for HER2 targeted therapy in mGC patients
references:
references:Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S , Decker T, Wittekind C, Lordick F.
Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S , Decker T, Wittekind C, Lordick F.
org/doi/abs/10.
1200/JCO.
20.
02761">https://ascopubs.
org/doi/abs/10.
1200/JCO.
20.
02761org/doi/abs/10.
1200/JCO.
20.
02761"> https://ascopubs.
org/doi/abs/10.
1200/JCO.
20.
02761 https://ascopubs.
org/doi/abs/10.
1200/JCO.
20.
02761Leave a message here
